Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Wuxi Biologics (Cayman) (WXIBF)
:WXIBF
Holding WXIBF?
Track your performance easily
WXIBF Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.27 - $4.00
Previous CloseN/A
Volume1.00K
Average Volume (3M)10.60K
Market Cap
$9.36B
Enterprise Value$48.05B
Total Cash (Recent Filing)$169.10M
Total Debt (Recent Filing)$895.65M
Price to Earnings (P/E)26.4
Beta0.76
Next Earnings
Mar 25, 2025EPS Estimate
0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.09
Shares Outstanding4,106,229,500
10 Day Avg. Volume26,636
30 Day Avg. Volume10,595
Standard Deviation0.19
R-Squared0.00388
Alpha0.00305
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)14.68
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market Cap5.14
Enterprise Value/Revenue4.14
Enterprise Value/Gross Profit9.95
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$3.28Price Target Upside44.49% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Wuxi Biologics (Cayman) News
PremiumCompany Announcements
WuXi Biologics Announces Hong Kong Office Relocation
PremiumCompany Announcements
Wuxi Biologics Sells Vaccines Ireland Facility for $500M
PremiumCompany Announcements
WuXi Biologics Welcomes New Non-Executive Director
PremiumCompany Announcements
WuXi Biologics Updates Board and Committees
PremiumCompany Announcements
WuXi Biologics Responds to U.S. House Draft BillPremiumCompany Announcements
WuXi Biologics Acquires Full Ownership of WuXi VaccinesBulls Say, Bears Say
Bulls Say
Global Market PositionWuXi Biologics is a leading player in the biologics CXO market, holding a 13% global market share and a dominant position in China.
Project ExpansionWuXi Bio added 151 new projects in 2024, the highest number in its history.
Revenue GrowthManagement reaffirmed its 2024 guidance, projecting 5–10% growth in both revenue and adjusted profit, while expressing confidence that revenue growth will accelerate in 2025.
Bears Say
Market SentimentDespite strong demand for antibody-drug conjugates, the potential passing of the Biosecure Act is causing negative market sentiment, leading to a decline in share prices for Chinese CXOs.
Political UncertaintyThere is a higher likelihood of the Biosecure Act being implemented due to a shift in political power, which adds uncertainty to WuXi Biologics' future operations in the US market.
Regulatory RiskThe Biosecure Act poses a significant threat to WuXi Biologics as it could ban US companies from dealing with the firm, affecting over half of its business.
---
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
5.68% Mutual Funds
0.02% Other Institutional Investors
87.56% Public Companies and
Individual Investors
WXIBF FAQ
What was Wuxi Biologics (Cayman) ’s price range in the past 12 months?
Wuxi Biologics (Cayman) lowest stock price was $1.27 and its highest was $4.00 in the past 12 months.
What is Wuxi Biologics (Cayman) ’s market cap?
Wuxi Biologics (Cayman) ’s market cap is $9.36B.
When is Wuxi Biologics (Cayman) ’s upcoming earnings report date?
Wuxi Biologics (Cayman) ’s upcoming earnings report date is Mar 25, 2025 which is in 66 days.
How were Wuxi Biologics (Cayman) ’s earnings last quarter?
Wuxi Biologics (Cayman) released its earnings results on Aug 21, 2024. The company reported $0.048 earnings per share for the quarter, missing the consensus estimate of $0.056 by -$0.008.
Is Wuxi Biologics (Cayman) overvalued?
According to Wall Street analysts Wuxi Biologics (Cayman) ’s price is currently Undervalued.
Does Wuxi Biologics (Cayman) pay dividends?
Wuxi Biologics (Cayman) does not currently pay dividends.
What is Wuxi Biologics (Cayman) ’s EPS estimate?
Wuxi Biologics (Cayman) ’s EPS estimate is 0.06.
How many shares outstanding does Wuxi Biologics (Cayman) have?
Wuxi Biologics (Cayman) has 4,106,229,500 shares outstanding.
What happened to Wuxi Biologics (Cayman) ’s price movement after its last earnings report?
Wuxi Biologics (Cayman) reported an EPS of $0.048 in its last earnings report, missing expectations of $0.056. Following the earnings report the stock price went up 2.667%.
Which hedge fund is a major shareholder of Wuxi Biologics (Cayman) ?
Currently, no hedge funds are holding shares in WXIBF
---
Wuxi Biologics (Cayman) Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$3.28 (44.49% Upside)
$3.28 (44.49% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-39.97%
12-Months-Change
Fundamentals
Return on Equity
6.75%
Trailing 12-Months
Asset Growth
7.57%
Trailing 12-Months
Company Description
Wuxi Biologics (Cayman)
Wuxi Biologics (Cayman), Inc. is an investment holding company, which engages in the discovery, development and manufacture of biologics services. Its services include testing; clinical drug substance cGMP manufacture; commercial drug substance cGMP manufacture; drug product cGMP fill and finish; antibody drug conjugates; regulatory affairs; and technologies and platforms. The company was founded on May 24, 2010 and is headquartered in Wuxi, China.
---
WXIBF Company Deck
---
WXIBF Earnings Call
Q2 2024
0:00 / 0:00
---
WXIBF Stock 12 Month Forecast
Average Price Target
$3.28
▲(44.49% Upside)
Technical Analysis
Best Analysts Covering WXIBF
1 Year
1 Year Success Rate
2/4 ratings generated profit
1 Year Average Return
+13.88%
reiterated a buy rating 5 months ago
Copying Jialin Zhang's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +13.88% per trade.
---